Ingredients - Articles and news items

Application note: Determination of APIs in tablets by NIR-Spectroscopy

Application note: Determination of APIs in tablets by NIR-Spectroscopy

Whitepapers / 15 December 2016 / Buchi

In this application note, Buchi discuss precise and robust calibration models for determining the active ingredient content of tablets…

Ingredients In-Depth Focus 2016

Ingredients In-Depth Focus 2016

Issue 5 2016, Supplements, Z Homepage promo / 20 October 2016 / European Pharmaceutical Review

In this Ingredients In-Depth Focus: Excipient quality and supplier interchangeability; Interpreting ICH’s evolving residual solvents guideline; Q&A with Meggle…

How digital transformation drives change and collaboration in the laboratory

Informatics, Ingredients, Webinars, Z Homepage promo / 8 September 2016 / Dassault Systèmes BIOVIA

This webinar shows how Lonza’s Specialty Ingredients sector successfully digitised and unified their global research operations with BIOVIA solutions…

Gérald Remaud, Head of the EBSI Team, University of Nantes

NMR – Recent developments for isotope profiling

Issue 3 2014, NMR Spectroscopy / 3 July 2014 /

Fraudulent misrepresentation, substitution or imitation of premium products has always been a problem for both the regulatory authorities and the pharmaceutical industry. The task of finding and preventing counterfeit products is particularly challenging1,2. Several analytical techniques are available to help characterise pharmaceutical compounds: physical profile; X-ray diffraction; infrared spectroscopy; mass spectrometry (MS); liquid or gas chromatography; and Nuclear Magnetic Resonance (NMR) spectrometry…

Dennis Douroumis

Hot melt extrusion processing for the development of sustained release products

Ingredients, Issue 2 2014 / 15 April 2014 / Dennis Douroumis, Reader in Pharmaceutical Sciences at the University of Greenwich and the Director of Centre for Innovation in Process Engineering and Research

Hot Melt Extrusion (HME) has attracted increased interest for the development of pharmaceutical dosage forms over the last decade. It is a versatile processing technology which produces extrudates in the form of solid dispersions and solid solutions. Among the various applications, HME has been adopted for the development of sustained release dosage forms by using a wide range of pharmaceutical excipients such as polymers or lipids. In this review, we highlight the development and recent trends of sustained release dosages manufactured by extrusion processing.

Pills Powder

Excipients in medicines for children: scientific and regulatory paradigms

Ingredients, Issue 2 2014 / 15 April 2014 / Ali Al-khattawi, Postdoctoral Research Associate, Aston University / Afzal R. Mohammed, Senior Lecturer in Pharmaceutics, Aston University

There is an ongoing debate over the use of pharmaceutical excipients in medicines for children, triggered by the increased number of formulations suitable for this target patient population. Pharmaceutical excipients can be regarded as essential / necessary enablers in formulation development. These are materials other than the ‘active pharmaceutical ingredient’ which are added to the formulation to achieve a specific function. This may include aiding in the processing or manufacture of the drug delivery system such as lubricants or flow aids, controlling the release of the active ingredient to achieve modified release, enhance patient acceptability by improving taste of medicines or to develop easily swallowed dosage forms.


Excipient selection in biologics and vaccines formulation development

Ingredients, Issue 1 2014 / 19 February 2014 / M. Babu Medi and Ramesh Chintala, Vaccine Drug Product Development, Merck & Co, Inc and Akhilesh Bhambhani, Novel Adjuvants, Formulation and Delivery Technologies, Merck & Co, Inc.

Excipients are an integral part of pharmaceutical products and play an important role in the formulation development of both small and large molecule pharmaceuticals. The type and extent of excipient use depends on several factors, including the type of active ingredient, route of administration, dosage form, target population and indication and so forth. With a growing number of protein therapeutics and vaccines in development, stabilisation during processing and storage presents a major challenge for the pharmaceutical industry. Biologics and vaccines are inherently unstable and prone to degradation by several physical and chemical degradation mechanisms. Therefore, a variety of excipients are required to stabilise biologics and vaccines during processing and storage. Selection and use of the appropriate excipients enable development of novel therapies and robust pharmaceutical products. The purpose of this article is to present an overview of the challenges associated with biologic and vaccine formulation development as well as different types of excipients used to stabilise these products.

Ingredients: In-depth focus 2013

Ingredients, Issue 3 2013, Supplements / 13 June 2013 / Matt Moran, Paul E. Luner

Revisiting a mutual recognition agreement approach for GMP inspections to secure the safety of the supply chain of APIs.
Solid form diversity of commonly used tableting excipients and its impact.


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...